Yao Ming Kant announced that the company learned that the US House Committee voted to pass a draft legislation numbered H.R. 8333 to the House of Representatives on May 15. We are convinced that Pharmacovich did not pose a national security risk to the US or any other country in the past, present, or future, and that the company has not been subject to any sanctions by US government agencies. The company also reiterated that Pharmacovich has no human genomics business, and that the company's various existing businesses do not involve the collection of human genomics data in the US, China, or any other region.
药明康德：公司在过去没有、现在和未来都不会对美国或任何其他国家构成国家安全风险
Yao Ming Kant: The company did not pose a national security risk to the US or any other country in the past, now, and in the future
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.